Standard BioTools vs Xilio Therapeutics
LAB and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LAB and XLO compare
Standard BioTools is the larger company, worth 5.2 times as much as Xilio Therapeutics ($252M against $49.0M).
Xilio Therapeutics grew revenue faster over the last twelve months (73.0% versus −4.8% for Standard BioTools).
Standard BioTools keeps more of each dollar of sales as profit, with a net margin of 100% compared with −20.9% at Xilio Therapeutics.
Standard BioTools scores higher on the StockData Score (12 against 11 for Xilio Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LAB | XLO |
|---|---|---|
| Size and price | ||
| Market cap | $252M | $49.0M |
| Share price | $0.643 | $8.47 |
| Change, 1 year | −45.0% | −24.8% |
| Change, 5 years | −85.7% | −97.3% |
| Beta (5Y) | 1.53 | 0.90 |
| Employees | 389 | 76 |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 4 (better) | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 2.9× | – |
| P/S | 3.0× | 0.9× (better) |
| P/B | 0.5× (better) | 0.7× |
| FCF yield | −32.7% (better) | −118% |
| Fair value | $4.90 | $32.67 |
| Margin of safety | 86.9% (better) | 74.1% |
| Growth | ||
| Revenue growth (TTM) | −4.8% | 73.0% (better) |
| Revenue growth, 5Y average | −9.2% | – |
| Profitability | ||
| Gross margin | 50.5% | – |
| Operating margin | −113% | −74.9% (better) |
| Net margin | 100% (better) | −20.9% |
| FCF margin | −97.6% (better) | −105% |
| Return on equity | 17.6% (better) | −38.2% |
| Return on invested capital | −60.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.10 (better) | 4.72 |
| Altman Z-score | −0.34 (better) | −3.85 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.4% | 58.9% |
| Held by insiders | 70.2% | – |
| Insider net buying, 12 months | $550K (better) | $38.3K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 1.9% | – |
Go deeper
- LAB stock overview
- LAB income statement
- LAB valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.